Thrombomodulin alfa is under clinical development by Asahi Kasei Pharma and currently in the Phase I and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Thrombomodulin alfa’s likelihood of approval (LoA) and phase transition for Sepsis took place on 04 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Thrombomodulin alfa Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Thrombomodulin alfa overview
Thrombomodulin alpha (Recomodulin) belong to of anti-thrombotic class. It is formulated as powder for solution for intravenous route of administration. Recomodulin indicated for the treatment of disseminated intravascular coagulation syndrome (DIC).
ART-123 (thrombomodulin alfa) is under development for the treatment of sepsis with disseminated intravascular coagulation, chemotherapy induced peripheral neuropathy and idiopathic pulmonary fibrosis.
It was also under development for the treatment of deep vein thrombosis and early allograft dysfunction.
Asahi Kasei Pharma overview
Asahi Kasei Pharma, a subsidiary of Asahi Kasei Corp, manufactures and markets diagnostic reagents, prescription drugs, and enzymes for diagnostic reagents. Its prescription drugs are used in the treatment of osteoporosis pain, disseminated intravascular coagulation, bone loss, dysuria accompanying benign prostatic hyperplasia, nocturia, proteinuria in nephrotic syndrome, and lupus nephritis, among others. Asahi Kasei Pharma offers assay kits for glycemic control and to detect prediabetes. The company’s pipeline products are intended for the treatment of chemotherapy-induced peripheral neuropathy, osteoporosis with high risk of fracture, Lupus nephritis and nephrotic syndrome, and severe sepsis with coagulopathy, among others. It has facilities in Shizuoka, and Nagoya, Japan. Asahi Kasei Pharma is headquartered in Tokyo, Japan.
Quick View Thrombomodulin alfa LOA Data
|Highest Development Stage|